Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. However, VIR also pivoted to oncology, discontinuing vaccines and viral immunotherapy, and partnered with Sanofi to leverage its PRO-XTEN platform for T-cell engagers. The strategic shift includes a 25% workforce reduction, saving $50 million annually by 2025, and focuses on advancing hepatitis delta and B treatments.
Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Conference Call Participants Paul Choi - Goldman Sachs Eric Joseph - JPMorgan Mike Ulz - Morgan Stanley Gena Wang - Barclays Alec Stranahan - Bank of America Nikola Gasic - Leerink Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright & Co.
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $1.22 per share a year ago.
Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High?
The consensus price target hints at a 258.4% upside potential for Vir Biotechnology (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024
24/7 Wall St. Insights Market pullbacks can make nervous investors leery of investing in industries that are speculative in nature.
Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Jennifer Towne - Executive Vice President and Chief Scientific Officer Mark Eisner - Executive Vice President and Chief Medical Officer Brent Sabatini - Chief Accounting Officer Conference Call Participants Phil Nadeau - TD Cowen Nikola Gasic - Leerink Paul Choi - Goldman Sachs Eric Joseph - J.P. Morgan Mike Ulz - Morgan Stanley Joseph Stringer - Needham & Company Alec Stranahan - Bank of America Operator Hello.
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.45 per share a year ago.
Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors. Positive Phase 2 trial results for chronic hepatitis delta highlight the company's potential to address unmet medical needs. Strategic collaborations include the Bill & Melinda Gates Foundation, Alnylam Pharmaceuticals, and Gilead Sciences.
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
